---
title: Augmenting Cognitive Training In Older Adults
nct_id: NCT02851511
overall_status: COMPLETED
phase: NA
sponsor: University of Florida
study_type: INTERVENTIONAL
primary_condition: Aging
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02851511.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02851511"
ct_last_update_post_date: 2024-04-17
last_seen_at: "2026-05-12T06:33:47.995Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Augmenting Cognitive Training In Older Adults

**NCT ID:** [NCT02851511](https://clinicaltrials.gov/study/NCT02851511)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 379
- **Lead Sponsor:** University of Florida
- **Collaborators:** University of Arizona, National Institute on Aging (NIA)
- **Conditions:** Aging
- **Start Date:** 2017-08-08
- **Completion Date:** 2022-04-30
- **CT.gov Last Update:** 2024-04-17

## Brief Summary

A two-phase adaptive randomized clinical trial will examine the individual and combined impact of pairing cognitive training with transcranial direct current stimulation (tDCS). tDCS is a method of non-invasive brain stimulation that directly stimulates brain regions involved in active cognitive function and could enhance neural plasticity when paired with a training task. We will compare changes in cognitive and brain function resulting from CT and ET combined with tDCS using a comprehensive neurocognitive, clinical, and multimodal neuroimaging assessment of brain structure, function, and metabolic state. Functional magnetic resonance imaging (FMRI) will be used to assess brain response during working memory, attention, and memory encoding; the active cognitive abilities trained by CT. Proton magnetic resonance spectroscopy (MRS) will assess cerebral metabolites, including GABA concentrations sensitive to neural plasticity. We hypothesize that: 1) tDCS will enhance neurocognitive function, brain function, and functional outcomes from CT, with combined CT and tDCS providing the most benefit; 2) Effects of tDCS on CT will be maintained up to 12 months following training, and 3) Neuroimaging biomarkers of cerebral metabolism, neural plasticity (GABA concentrations) and functional brain response (FMRI) during resting vs. active cognitive tasks will predict individual response to tDCS.

## Eligibility

- **Minimum age:** 65 Years
- **Maximum age:** 89 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion criteria:

1. Age 65 to 89 years; this age group was selected because it is at high risk of age-related cognitive decline and have a sufficiently long life expectancy to participate in the study.
2. Evidence of age-related cognitive decline in the Cognitive Training assessment defined by performance below the 80th percentile.
3. Ability to participate in the intervention and attend training sessions; willingness to be randomized to either treatment group.

Exclusion criteria:

1. Neurological disorders (e.g., dementia, stroke, seizures, traumatic brain injury).
2. Evidence of cognitive impairment (as defined by NACC UDS performance below 1.5 standard deviations on age/sex/education normative data in at least one cognitive domain).
3. Past opportunistic brain infection.
4. Major psychiatric illness (schizophrenia, intractable affective disorder, current substance dependence diagnosis or severe major depression and/or suicidality.
5. Unstable (e.g., cancer other than basal cell skin) and chronic (e.g. severe diabetes) medical conditions.
6. MRI contraindications (e.g., claustrophobia, metal implants).
7. Physical impairment precluding motor response or lying still for 1 hr and inability to walk two blocks without stopping.
8. Currently on GABA-ergic or glutamatergic medications, or on sodium channel blockers.
9. Left-handedness.
```

## Arms

- **Cognitive Training + Active Stimulation** (EXPERIMENTAL) — This arm receives cognitive training combined with active tDCS.
- **Cognitive Training + Sham Stimulation** (EXPERIMENTAL) — This arm receives cognitive training combined with sham tDCS.
- **Educational Training + Active Stimulation** (EXPERIMENTAL) — This arm receives educational training combined with active tDCS.
- **Educational Training + Sham Stimulation** (EXPERIMENTAL) — This arm receives educational training combined with sham tDCS.

## Interventions

- **Cognitive Training** (BEHAVIORAL) — Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
- **tDCS (active stimulation)** (DEVICE) — A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
- **tDCS (sham stimulation)** (DEVICE) — Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
- **Educational Training** (BEHAVIORAL) — Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.

## Primary Outcomes

- **Improvement in Cognitive Ability.** _(time frame: Change from baseline to post assessment (3 months).)_ — Composite measure of cognitive ability as defined by NIH toolbox fluid cognition fully corrected T-score. Minimum change = -13, Maximum change = 26. Higher scores mean a better outcome. The minimum and maximum for Cognitive Training + Active Stimulation, Cognitive Training + Sham Stimulation, Educational Training + Active Stimulation and Educational Training + Sham Stimulation are (-13, 20) and (-10, 26), respectively. This outcome is measured for the participants who received cognitive training, including both Phase I and Phase II participants, N=334 (Phase I N=42, Phase II N=292).

## Secondary Outcomes

- **Phase I POSIT BrainHQ Cognitive Training Composite Performance Measure.(Phase I POSIT Z-Score)** _(time frame: Baseline to post assessment (3 months).)_

## Locations (3)

- University of Arizona, Tucson, Arizona, United States
- Village of Gainesville, Gainesville, Florida, United States
- University of Florida McKnight Brain Institute, Gainesville, Florida, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of arizona|tucson|arizona|united states` — added _(2026-05-12)_
- `locations.village of gainesville|gainesville|florida|united states` — added _(2026-05-12)_
- `locations.university of florida mcknight brain institute|gainesville|florida|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02851511.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02851511*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*